Randomised, double-blind, multicentre clinical trial to evaluate the efficacy and safety of topical metformin in adjuvant to daylight photodynamic therapy in actinic keratoses.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520798-38-00

Acronym

ICI21/00031

Enrollment

135

Registered

2025-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic keratoses

Brief summary

Patients will receive treatment for 12 weeks and will be observed for 36 weeks after completion of treatment to assess clinical efficacy and adverse effects.

Interventions

DRUGMETFORMIN

DRUGThe placebo components are propylene glycol

DRUGneoPCLO/W

DRUGfenonip XB and purified water.

DRUGMETHYL AMINOLEVULINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Patients will receive treatment for 12 weeks and will be observed for 36 weeks after completion of treatment to assess clinical efficacy and adverse effects.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026